Content by Keyword: Dementia and Alzheimer's Disease

Significant advances in the use of imaging and biomarkers in brain, blood, and spinal fluid have made it possible to detect the onset of AD/ADRD and track its progression, with the hope that it will be possible to monitor the effect of treatment in people with the disease. Without these advances, these neurodegenerative processes could only be eva

HHS and its federal partners will expand clinical trials on pharmacologic and non-pharmacologic ways to prevent AD/ADRD and manage and treat its symptoms. The Federal Government will address the challenge of enrolling enough people in clinical trials who are representative of the country's population, including racial and ethnic populations that a

Research agencies undertake research planning processes on an ongoing basis, but a special effort is needed to identify the priorities and milestones to achieve Goal 1. The actions below will identify the priorities, establish milestones, and ensure that appropriate stakeholders are involved in the planning process aimed at minimizing AD/ADRD as a

Return to National Alzheimer's Project Act Home Page National Plan to Address Alzheimer's Disease and Other NAPA Documents Page National Plans to Address Alzheimer's Disease Page

AAA Area Agency on Aging AAIC Alzheimer's Association International Conference ABA American Bar Association ACL Administration for Community Living ACP

Hebert LE, Weuve J, Scherr PA, Evans DA. "Alzheimer's Disease in the United States (2010-2050) Estimated Using the 2010 Census." Neurol, 2013; 80:1778-1783. Burns A, Iliffe S. "Alzheimer's Disease." BMJ, 2009; 338:b158. Alzheimer's Disease Education and Referral (ADEAR) Center. Alzheimer's Disease Fact Sheet. U.S. Department o

Action Number Action Description (from Plan) Method of Action Lead Agency Partner(s)

Administration for Children and Families (ACF) Administration for Community Living (ACL) Administration on Aging (AoA) Administration on Intellectual and Developmental Disabilities (ADD) Agency for Healthcare Research and Quality (AHRQ) Centers for Disease Control and Prevention (CDC) Centers for Medicare & Medicaid Services (CMS)

The Federal Government is committed to better understanding AD/ADRD and its impact on PWD, families, the health and long-term care systems, and society as a whole. Data and surveillance efforts are paramount to tracking the burden of AD/ADRD on individual and population health and will be used to identify and monitor trends in risk factors associa

Most of the public is aware of AD/ADRD; more than 85% of people surveyed can identify the disease and its symptoms. AD/ADRD is also one of the most feared health conditions, yet there are widespread and significant public misperceptions about diagnosis and clinical management. Misperceptions lead to delayed diagnosis and to people with the disease

People with AD/ADRD and their families need supports that go beyond the care provided in formal settings such as doctors' offices, hospitals, or nursing homes. Families and other informal caregivers play a central role. Supporting people with AD/ADRD and their families and caregivers requires giving them the tools that they need, helping to plan f

Providing all people with AD/ADRD with the highest-quality care in the most efficient manner requires a multi-tiered approach. High-quality care requires an adequate supply of culturally-competent professionals with appropriate skills, ranging from direct care workers to community health and social workers to primary care providers and specialists

Research continues to expand our understanding of the causes of, treatments for, and prevention of AD/ADRD. This goal seeks to develop effective prevention and treatment modalities by 2025. Ongoing research and clinical inquiry can inform our ability to delay onset of AD/ADRD, minimize its symptoms, and delay its progression.

National Alzheimer's Project Act On January 4, 2011, the National Alzheimer's Project Act (NAPA) (Public Law 111-375) was signed into law. The Act defines "Alzheimer's" as Alzheimer's disease and related dementias (AD/ADRD) and requires the Secretary of the U.S. Department of Health and Human Services (HHS) to establish the National Alzheimer's

ADVISORY COUNCIL ON ALZHEIMER'S RESEARCH, CARE, AND SERVICES Monday, October 21, 2019 Printer Friendly Version in PDF Format (7 PDF pages)  

ADVISORY COUNCIL ON ALZHEIMER'S RESEARCH, CARE, AND SERVICES Monday, October 21, 2019 Printer Friendly Version in PDF Format (10 PDF pages)   Long-Term Services and Supports Federal Update   Administration for Community Living  

ADVISORY COUNCIL ON ALZHEIMER'S RESEARCH, CARE, AND SERVICES Monday, October 21, 2019 Printer Friendly Version in PDF Format (4 PDF pages)   Clinical Subcommittee Update Ellen Blackwell, MSW

ADVISORY COUNCIL ON ALZHEIMER'S RESEARCH, CARE, AND SERVICES Monday, October 21, 2019 Printer Friendly Version in PDF Format (4 PDF pages)   Alzheimer’s Disease and Related Dementias Research Update Richard J. Hodes, M.D. Director, NIA

ADVISORY COUNCIL ON ALZHEIMER'S RESEARCH, CARE, AND SERVICES Monday, October 21, 2019 Printer Friendly Version in PDF Format (23 PDF pages)  

ADVISORY COUNCIL ON ALZHEIMER'S RESEARCH, CARE, AND SERVICES Monday, October 21, 2019 Printer Friendly Version in PDF Format (9 PDF pages)   Risks and Costs of Dementia at Older Ages Melissa Favreault and Richard W. Johnson Urban Institute Judith Dey, Helen Lamont, William Marton ASPE